Overview
Now Enrolling Participants for a Rheumatoid Arthritis Research Study Near You
Living with Rheumatoid Arthritis symptoms can be frustrating. If you’re seeking help, consider joining a research study that’s testing investigational treatments for Rheumatoid Arthritis.
Medical research helps doctors and scientists discover better treatments and improve healthcare for everyone. By joining as a volunteer, you play a key role in making these important advancements possible.
About the Study
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MultipleAscending Doses of GS-0151 in Adult Participants with Rheumatoid Arthritis
This study’s purpose is to determine the safety, tolerability (how well people can handle it), and efficacy (how well it works) of a new investigational drug, for people with rheumatoid arthritis.
Who Can Join
To qualify, you must meet the following conditions:
- 18 to 75 years old
- Diagnosed with Rheumatoid Arthritis for at least 3 months prior to screening
- Currently taking one or two csDMARDs for at least 12 weeks (with the dose unchanged for the last 6 weeks):
- Methotrexate: 7.5 to 25 mg/week (oral or injectable)
- Hydroxychloroquine: up to 400 mg/day (oral), or Chloroquine up to 250 mg/day (oral)
Sulfasalazine: 1 to 3 g/day (oral)
Leflunomide: 10 to 20 mg/day (oral)
- Not diagnosed with any generalized musculoskeletal disorder
- BMI is between 18-35
Exclusion Criteria:
- Patients with generalized osteoarthritis or any systemic inflammatory condition other than Rheumatoid Arthritis (RA) are excluded. Examples of such conditions include, but are not limited to:
- Juvenile idiopathic arthritis
- Inflammatory bowel disease-associated arthropathies
- Systemic lupus erythematosus
- Scleroderma inflammatory myopathy
- Mixed connective tissue disease
- An overlap syndrome
- Systemic vasculitis
- Gout
- Current moderate-to-severe congestive heart failure
- Prohibited concurrent medications/treatments would include:
- Biologic or targeted synthetic DMARDs (b/tsDMARDs), including any biosimilars and generics.
- B cell–depleting agents (e.g., rituximab).
- High-potency opiates.
*Other criteria may apply
Not sure if you qualify? That’s okay.
A member of our recruitment team will review your medical history and medications with you to see if this study may be right for you.
What to Expect
Study Duration:
Up to 34 weeks / 250 days
Study Visits:
Up to 20 site visits
The entire clinical trial, including screening, treatment, and follow-up, will last up to 19 weeks for each participant.
Compensation:
Participants may receive compensation up to $2700